Client NewsRoquefort Therapeutics plc: Pre-clinical Program & Transaction Update
Roquefort Therapeutics (LSE:ROQ, OTCQB:ROQAF), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to provide an update on the progress of its proprietary Midkine (“MDK”) antisense oligonucleotide* pre-clinical drug development program, on its patent portfolio and on the Oncogeni transaction.
OPEN AN ACCOUNT
If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.
Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.